Romidepsin (FK228, Depsipeptide)

For research use only.

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

126 publications

Romidepsin (FK228, Depsipeptide) Chemical Structure

CAS No. 128517-07-7

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 13415.22 In stock
RMB 1285.83 In stock
RMB 3910.79 In stock
RMB 5710.89 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Romidepsin (FK228, Depsipeptide) has been cited by 126 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 M1zDRWNmdGxiVnnhZoltcXS7IFHzd4F6 MlG1Nk42NTF3IH7N MmD3O|IhcA>? Ml;CbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MmDzNlU4QTB7MEe=
U2932  NF\mWlhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4PteFIvPS1zNTDuUS=> MYS3NkBp MXXpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NGHGR5ozPTd7MEmwOy=>
OCI-LY7 NWKxTIlpS2WubDDWbYFjcWyrdImgRZN{[Xl? M1uxOFIvPS1zNTDuUS=> MX:3NkBp MnvDbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M{PlVlI2PzlyOUC3
Farage NIL1fHRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVGyMlUuOTVibl2= NEjWfGE4OiCq NV;L[2NmcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MlvTNlU4QTB7MEe=
LY7/EBV MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NILFc|czNjVvMUWgcm0> M{Lnd|czKGh? NFS1WmJqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NFnQWG4zPTd7MEmwOy=>
U2932/EBV NIrFS3lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHTDO5UzNjVvMUWgcm0> MVy3NkBp MnfRbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MnjlNlU4QTB7MEe=
HCT116 NGTHdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm5OU02ODByIH7N M2LQeVI1KGh? NIr2ZZdFVVOR MUXpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= M33GVFI2PDl{NUG1
ACH-2 NIPGfWFHfW6ldHnvckBCe3OjeR?= M2Lx[lEuQSCwTR?= NVPZSI93OjRiaB?= M1\Ne4lv\HWlZYOgTGlXNTFiRX72JIV5eHKnc4Ppc44> MkfvNlUyPDl2Nke=
MCF-10A MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XQRmlEPTB;MD6xO:KyOC5yMTDuUS=> MXOyOFk2PDh3Nh?=
MCF-7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3VUGM6UUN3ME2xMlExyrFyLkKwJI5O MoOxNlQ6PTR6NU[=
SK-BR-3 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrPT2JxUUN3ME2xMlAxyrFyLkO1JI5O MlLFNlQ6PTR6NU[=
MDA-MB-231 NUHSUohWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvrTWM2OD1yLk[4xtExNjF2IH7N NWHxR4FlOjR7NUS4OVY>
PC3 M4rVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwNkZCtVAvOzVibl2= MYKyOFk2PDh3Nh?=
HCT116 MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTrSJV2UUN3ME2xMlAxyrFyLkCwJI5O NHXwflgzPDl3NEi1Oi=>
HCT116-p21-/- M{j3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwMkdCtVAvOzdibl2= MoLINlQ6PTR6NU[=
S1 M1XZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfIOG9sUUN3ME23MlY4yrFyLkK5JI5O NVnuWWFiOjR7NUS4OVY>
SW620 M{jqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF65NWlKSzVyPUCuPVPDuTBwMkmgcm0> M3n6PFI1QTV2OEW2
LOX-IMVI M1K1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwOEhCtVAvODNibl2= MYqyOFk2PDh3Nh?=
UACC-62 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:yTWM2OD1yLkW2xtExNjF4IH7N NWrITJRIOjR7NUS4OVY>
MDA-MB-435 NUHWWJZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm1PGtSUUN3ME2wMlkxyrFyLkC2JI5O M3q3blI1QTV2OEW2
SF-295 M2jQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TmeWlEPTB;MD64POKyOC5zNTDuUS=> M4PQelI1QTV2OEW2
A549 M1;nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlezTWM2OD1zLkK2xtExNjJ2IH7N M2nZd|I1QTV2OEW2
H460 NUnjV2cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJwNUlCtVAvQDBibl2= NWTQ[JdIOjR7NUS4OVY>
EKVX NF7EfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHOeWk6UUN3ME2xMlM{yrFyLkO0JI5O MWWyOFk2PDh3Nh?=
H146 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;NR453UUN3ME2wMlIzyrFyLkC3JI5O NXLa[4ZsOjR7NUS4OVY>
H526 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\leZhXUUN3ME2wMlE2yrFyLkCzJI5O MlLmNlQ6PTR6NU[=
HuT-78 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzyXoJKSzVyPUGuO|PDuTBwNESgcm0> MUCyOFk2PDh3Nh?=
HA M4rON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSwNE43OjVvMUDuUS=> NYLqOopMPDhiaB?= NH3yXXlqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? NEXoeYEzPDd5MUWxNC=>
MS-275 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jCOlAvPjJ3LUGwcm0> M2f5bVQ5KGh? M3X2Tolv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj NYD2Z|lZOjR5N{G1NVA>
CD4 T M4C4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWC0PEBp MUnFR|UxRTRwNdMxNU4xKG6P MlraNlQ4OjJ2NUS=
CD4 T M1nmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC3VGM1QCCq MmnWR2M2OD1zMEhCtVEzPiCwTR?= NX\rW3huOjR5MkK0OVQ>
CD4+ T NYfTb3hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j1bGVEPTB;MzDuUS=> M3nH[|I1PDl3MUC1
A549 M4HweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm4PG4yOOLCk{GwNOKhdk1? NVLIOo9FOjRxM{[vOFghcA>? NF\WUGJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MXmyOFQ5PTd7OR?=
JJN3 NI[0U2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmyOE81QCCq M2PWbWVEPTB:MfMAjY5OQyB2OPMAjYg> NGCxVXozPDB|MEG1NC=>
OPM-2 NWnlVZY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;D[IIzPC92ODDo NFrZb49GSzVyc{2x5qCKdk19IES45qCKcA>? M{PielI1ODNyMUWw
RPMI-8226 M37KXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTKdYN{OjRxNEigbC=> MormSWM2OHN;MT645qCKdk19IES45qCKcA>? NXG3fYFjOjRyM{CxOVA>
U266 NHvKW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOyOE81QCCq M3zObmVEPTC|PUGw5qCKdk19IES45qCKcA>? MkHkNlQxOzBzNUC=
CA46 NYq5SGFjSXCxcITvd4l{KEG|c3H5 MXe2JIg> NV3UPYRjcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= M1zZOVI{QTZ4MU[0
DG75 NF\BcGFCeG:ydH;zbZMhSXO|YYm= MV:2JIg> NE\QZlVqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? NV\4cYNHOjN7Nk[xOlQ>
Ramos MVjBdI9xfG:|aYOgRZN{[Xl? NXLORph[PiCq M2\URYlv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> MYGyN|k3PjF4NB?=
ST486 NV3CSG1USXCxcITvd4l{KEG|c3H5 NG[xdWo3KGh? M4DneYlv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NVfhcJY{OjN7Nk[xOlQ>
HuT78 M1m1[mFxd3C2b4Ppd{BCe3OjeR?= M{nTRVEwOTBxMUCwJI5O MXK0PEBp NWHkSFlLcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> NHHp[YczOzV|MkezNi=>
DpVp35 NHHtZmxCeG:ydH;zbZMhSXO|YYm= MXmxM|ExNzFyMDDuUS=> M2nlWVQ5KGh? M{HOb4lv\HWlZYOgZox2dnRiYYDvdJRwe2m| MoGxNlM2OzJ5M{K=
DpVp50 NI\tXlNCeG:ydH;zbZMhSXO|YYm= MYGxM|ExNzFyMDDuUS=> MXm0PEBp M1rjd4lv\HWlZYOgZox2dnRiYYDvdJRwe2m| NVPETYozOjN3M{K3N|I>
DpP75  MXHBdI9xfG:|aYOgRZN{[Xl? MmDkNU8yOC9zMECgcm0> NIDyNnQ1QCCq M3XDZYlv\HWlZYOgZox2dnRiYYDvdJRwe2m| M3vIOVI{PTN{N{Oy
SKOV-3 NXHYSJV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTBOXVuOeLCk{Kwcm0> NEfRUnM4OiCq NWXsfnp6TE2VTx?= Mn7tdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NFzXTpYzOzBzMEO0PC=>
Brca1 WT NGG2TnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHSNJEy6oDVMkDuUS=> M3judVczKGh? MmT6SG1UVw>? NX\NZZp5emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? M{TqcVI{ODFyM{S4
Brca1 Null MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKx5qCUOjCwTR?= NWDtSJJ2PzJiaB?= M1TMOmROW09? MlXndoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NGTWNVMzOzBzMEO0PC=>
OVCAR-8  NXP2VXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrXUFRUOeLCk{Kwcm0> NWqzZVRmPzJiaB?= MX3EUXNQ NYTIUZZ3emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NV3BbHNvOjNyMUCzOFg>
NCI/ADR-RES NIPNenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j2OVHjiJN{MH7N M4\oflczKGh? MYfEUXNQ NG\ZXnVz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NF\TVJUzOzBzMEO0PC=>
HCT116 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHTOUBvVS13MDFOwG0> NIC1SW8zPCCq MVTEUXNQ NH3Ud|NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NFHnXJYzOjl{NEm1PC=>
RKO NVmyeJBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTuNlJTPSCwTT21NEDPxE1? NFThUnYzPCCq MkXsSG1UVw>? NGC3UGxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MXqyNlkzPDl3OB?=
CO115 NXHzS|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPmVWE2KG6PLUWwJO69VQ>? NIrBZ|YzPCCq NEjNSpNFVVOR MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MUWyNlkzPDl3OB?=
HFS NVP5NldlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrsOUBvVQ>? MmHZNlQwPDhxN{KgbC=> MWPpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 NX3NRYpXOjJzME[yPFI>
LNCaP NXnaPJhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;uZlUhdk1? M3fFVFI1NzR6L{eyJIg> MUfpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 MWiyNlExPjJ6Mh?=
A549 NVfMdJpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\XOGI2KG6P MnzlNlQwPDhxN{KgbC=> M4m4S4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NGnQ[lYzOjFyNkK4Ni=>
697  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m4NGlEPTEkgJm95qCKOi53wrDuUS=> NYe2cZVVOjF3M{iyNVY>
697-R MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|Ux6oDLPfMAjVgvPsLibl5CpC=> NVezb|N5OjF3M{iyNVY>
HUT78 M1vGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfTNnhWUUN3ME2xJI5O MnvjNlEyQTh3NEW=
THJ-16T NEi1WFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\SO5EyKG6P M1HwcVI1KGh? MorIbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NUK4RXFFOjB6MUC1Olg>
HCT116 MmXLSpVv[3Srb36gRZN{[Xl? NGrpXGkzOCCwTR?= NY\HRmtiQCCq MoLncY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w M3zIdVIxPzN7NEW0
B104  NX;4UI5KTnWwY4Tpc44hSXO|YYm= MWKyJI5O MXuyOE81QC95MjDo MlywbY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi Mn6zNlA3QDZ3MEW=
HL-60  M4\rUWN6fG:2b4jpZ4l1gSCDc4PhfS=> NYK0TWFYOS13MECgcm0> MVeyOEBp Ml\LbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M1fMNVIxPjJ2MU[z
HP100 M4rDVWN6fG:2b4jpZ4l1gSCDc4PhfS=> NGjWe3AyNTVyMDDuUS=> M3[5PVI1KGh? MYXpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MUmyNFYzPDF4Mx?=
HL-60  NX3RTlhHTnWwY4Tpc44hSXO|YYm= MlvoNVAhdk1? MnXCOE83NzF4IHi= M{jmXolv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= M1jF[FIxPjJ2MU[z
HP100 NUXB[FBMTnWwY4Tpc44hSXO|YYm= NEe1XZgyOCCwTR?= NXvYW21zPC94L{G2JIg> NYLrO|hDcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo NFHObXMzODZ{NEG2Ny=>
HL-60  M2nMNGZ2dmO2aX;uJGF{e2G7 NWSyOHJ4OTBvNUCwJI5O NIWxbWk1KGh? NH:yPGVl\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= MY[yNFYzPDF4Mx?=
HP100 Mo\TSpVv[3Srb36gRZN{[Xl? NYfJUpl5OTBvNUCwJI5O NH\nTIs1KGh? MUDk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? Moe3NlA3OjRzNkO=
11z NX:4ZXd{U2mwYYPlJGF{e2G7 MWizMVExOCCwTR?= NWjEfXZlemWmdXPld{BJTEGFIHXufplu[XSrYzDhZ5Rqfmm2eTCoTWM2OMLiPTC2MlUhyrFiMD62JI5ud2xxTDm= NEfzbIEzODZyNUG0OC=>
SKOV-3 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fQN|QwQC9zNjDuUS=> NYLvd|RmPDhiaB?= MmnybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NFjOSVczODRyNEW2OC=>
OVCAR-3 M{\Ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj2O206PC96L{G2JI5O MkHGOFghcA>? NGn6bI9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M4jkOFIxPDB2NU[0
HBL-2 NFzwdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7OVVhEOi1zMDDuUS=> NUDpSZlsOjRiaB?= MlqyTWM2OD12LkOgcm0> Ml72NlAxPjhyOEC=
Jeko-1 NY\zcpJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqyMVUxKG6P MlXSNlQhcA>? NFX1[W5KSzVyPUGxJI5O NIHJO|QzODB4OEC4NC=>
Granta-519 M4fUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12y[|UuPDBibl2= M{DySFI1KGh? M2TCV2lEPTB;NUiuOUBvVQ>? NUn6UYlHOjByNkiwPFA>
L1236 NV;OXGc6S3m2b4TvfIlkcXS7IFHzd4F6 MX:xJI5ONTFyMDFOwG0> M4fae|Q5KGh? NGLJRW9GSzVyPUCuNFch|ryP MVexPVI{OzR5MB?=
L428 NVHoSIJ6S3m2b4TvfIlkcXS7IFHzd4F6 M{LDUFEhdk1vMUCwJO69VQ>? MofrOFghcA>? NUjCco0{TUN3ME2wMlQ{KM7:TR?= NXTWU5V6OTl{M{O0O|A>
KM-H2 M4rkfGN6fG:2b4jpZ4l1gSCDc4PhfS=> NWP2[Wk1OSCwTT2xNFAh|ryP M4XTOlQ5KGh? MnPISWM2OD1yLkW4JO69VQ>? NFS0W2cyQTJ|M{S3NC=>
L540Cy NYr6UINoS3m2b4TvfIlkcXS7IFHzd4F6 NWDXO4dWOSCwTT2xNFAh|ryP MU[0PEBp NYGxVHZXTUN3ME2wMlE3KM7:TR?= NHf2OXEyQTJ|M{S3NC=>
G401 NULIW45mTnWwY4Tpc44hSXO|YYm= NWPsT4R[OTBibl2= NIjOVnczPC92OD:3NkBp MUDEUXNQ M4TWZolv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MkG1NVkzOjF3OE[=
STM91-01 MVXGeY5kfGmxbjDBd5NigQ>? MlTGNVAhdk1? MUGyOE81QC95MjDo MkfFSG1UVw>? MmTXbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NYS1Z2VtOTl{MkG1PFY>
SJSC  MUPGeY5kfGmxbjDBd5NigQ>? MX:xNEBvVQ>? M4rsPVI1NzR6L{eyJIg> NUPGUGFWTE2VTx?= M4LYN4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NVS3SJA6OTl{MkG1PFY>
BT16  MkC5SpVv[3Srb36gRZN{[Xl? MYmxNEBvVQ>? NFnFWGQzPC92OD:3NkBp NYC5PFljTE2VTx?= MYnpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M13lSVE6OjJzNUi2
NCI-H1299 MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTRwNtMxNE4zKG6pL33s MVuxPVE4QTh7MB?=
NCI-2882 M2niV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPYTWM2OD1zLkdCtVAvODRibnevcYw> Moe1NVkyPzl6OUC=
HCC95 M2LPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXBWFNKSzVyPUKuOeKyOC5yNTDu[{9udA>? MlS3NVkyPzl6OUC=
NCI-H23 NIPNVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof1TWM2OD1{LkpCtVAvOiCwZz;tcC=> M37RWVE6OTd7OEmw
NCI-H157 NFXQfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwNtMxNE4xOiCwZz;tcC=> NVW1OG85OTlzN{m4PVA>
NCI-H460 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrvU486UUN3ME2yMlHDuTBwMEegcocwdWx? M{X0N|E6OTd7OEmw
NCI-H1975 NI\mUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3zUZpKSzVyPUGuN:KyOC5yNDDu[{9udA>? M1i4V|E6OTd7OEmw
NCI-H820 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS4bGhuUUN3ME2yMlTDuTBwMTDu[{9udA>? NF3ye4IyQTF5OUi5NC=>
NCI-H1650 NEj5S49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\GO|lKSzVyPUSuPeKyOC5|IH7nM41t NH\vdYcyQTF5OUi5NC=>
DTC1 M3\Qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHMTWM2OD1yLkWxJI5O M{TWOVE5PTZ4MkS2
KAO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjTN3dKSzVyPUCuPVEhdk1? MXyxPFU3PjJ2Nh?=
SU-CCS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL5TWM2OD1yLki5JI5O Ml\uNVg2PjZ{NE[=
SYO-1 NInZcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWzSGpKSzVyPUCuOlchdk1? MmrpNVg2PjZ{NE[=
FUJI MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;BZmlEPTB;MT6zNUBvVQ>? NFTRb5IyQDV4NkK0Oi=>
SKNMC MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwMUegcm0> M{PZ[lE5PTZ4MkS2
402-91 M{nXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPhTWM2OD1zLkK2JI5O M{PCdVE5PTZ4MkS2
1765-92 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m3N2lEPTB;MT63O{BvVQ>? MWixPFU3PjJ2Nh?=
JN-DSRCT-1 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D2cWlEPTB;MT6yOUBvVQ>? NF23TYYyQDV4NkK0Oi=>
NMS-2PC NI\yU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwOEGgcm0> M4rKdVE5PTZ4MkS2
HL60 MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnaXFVYUUN3ME2xMlg3KG6P MVGxPFU3PjJ2Nh?=
A549 NWHMcpRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzWXFVKSzVyPUOuNlQhdk1? M{jNS|E5PTZ4MkS2
SW480 NHvNcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHezdlFKSzVyPUKuOlkhdk1? NHLsclcyQDV4NkK0Oi=>
MCF7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH5PXhKSzVyPUOuOVUhdk1? MlLHNVg2PjZ{NE[=
PC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC4U5VKSzVyPUKuOVEhdk1? M4nZdFE5PTZ4MkS2
MMRU NYrlOGZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLvTWM2OD1{LkW3JI5O MUSxPFU3PjJ2Nh?=
Hs68 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr0TWM2OD1-MUCgcm0> NWOyNYY5OTh3Nk[yOFY>
hMSC-001F M3XDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWntb2JKUUN3ME2+NVAhdk1? MmHqNVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

- Collapse

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

- Collapse
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176
Smiles CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting Drug: Tenalisib|Drug: Romidepsin T Cell Lymphoma Rhizen Pharmaceuticals SA March 12 2019 Phase 1|Phase 2
NCT02616965 Recruiting Drug: Romidepsin|Drug: Brentuximab vedotin Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics Inc.|Celgene Corporation February 22 2017 Phase 1
NCT02616874 Completed Drug: MVA.HIVconsv vaccine|Drug: Romidepsin HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN Checkpoint February 2016 Phase 1
NCT03141203 Active not recruiting Drug: Romidepsin|Drug: Carfilzomib Peripheral T Cell Lymphoma University of Birmingham|Bloodwise|Celgene|Amgen July 13 2015 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID